Table 3:
Results from repeat measurement of FGF-21 in serum, listed by patients’ numbers
| Diagnosis | FGF-21 concentration in serum (pg/mL) |
Disease progression between measurements | ||
|---|---|---|---|---|
| 2009 or 2010 | 2011 | |||
| 4 | MELAS | 580 | 1048 | Active disease progression |
| 15 | Mitochondrial myopathy | 586 | 915 | Moderate disease progression |
| 16 | Mitochondrial myopathy | 570 | 514 | Stable disease |
| 78 | Alpers’ hepatoencephalopathy | 1062* | 2250 | Progressive disease, remitting status epilepticus |
Analysis done in 2010.